Bioline RX Ltd Sponsored ADR (BLRX)
NASDAQ:BLRX
Want to see BLRX full AI Analyst Report?
BLRX Stock Chart & Stats
$2.45
-$0.02(-10.62%)
At close: 4:00 PM EST
$2.45
-$0.02(-10.62%)
Day’s Range― - ―
52-Week Range$2.15 - $7.77
Previous CloseN/A
Volume8.80M
Average Volume (3M)23.61K
Market Cap
$14.03M
Enterprise Value$21.46M
Total Cash (Recent Filing)$20.88M
Total Debt (Recent Filing)$10.15M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Aug 13, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.48
Shares Outstanding4,368,295
10 Day Avg. Volume24,146
30 Day Avg. Volume23,614
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.63
Price to Sales (P/S)9.57
P/FCF Ratio-1.39
Enterprise Value/Market Cap1.53
Enterprise Value/Revenue18.17
Enterprise Value/Gross Profit24.18
Enterprise Value/Ebitda-12.82
Forecast
1Y Price Target
$12.00Price Target Upside389.80% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.55
Revenue Forecast (FY)$1.49M
Bulls Say, Bears Say
Bulls Say
Commercial Product Royalties (APHEXDA) Via Partner CommercializationHaving a marketed product (APHEXDA) that generates royalties through a commercialization partner creates a recurring, partner-driven revenue stream and reduces direct U.S. commercial cost burdens. Over the next several quarters, this contractual royalty profile can provide predictable cash inflows to fund R&D and operations if partner sales scale.
GLIX1 First-in-human Trial And Encouraging Preclinical ProfileAdvancing GLIX1 into a Phase 1/2a trial materially de-risks early development and transitions the program toward clinical value inflection points. The first-in-class TET2-activating mechanism and brain-penetrant profile target a high unmet need in glioblastoma, offering durable pipeline upside beyond current royalty revenue if clinical signals appear.
Patent Protection Plus Leaner, R&D-focused Operating ModelA granted U.S. patent through 2040 provides a substantive IP moat for GLIX1, underpinning long-term exclusivity. Coupled with a deliberate shift to a leaner, R&D-centric operating model and reduced selling costs, this structural repositioning preserves cash and concentrates resources on clinical milestones that drive strategic value over the next 2–3 years.
Bears Say
Persistently Negative Operating And Free Cash FlowSustained negative operating and free cash flow means the company must rely on existing cash, partnerships, or external financing to fund trials. Even with improved burn in 2025, ongoing negative free cash flow and limited runway increase the probability of dilutive financing or constrained development pacing over the next several quarters.
Sharp, Volatile Revenue DeclineA precipitous revenue drop undermines near-term self-funding capacity and highlights dependence on a narrow revenue base (royalties and partner payments). This volatility complicates multi-quarter planning and raises execution risk: sustained top-line weakness could force further cuts or external capital needs before clinical value is realized.
Moderate Leverage And Compressed Equity Restricting FlexibilityMeaningful debt relative to a shrunken equity base reduces balance-sheet flexibility if losses continue. Compressed equity and prior reliance on capital changes limit options for non-dilutive funding and increase the likelihood that the company will need to raise capital on potentially unfavorable terms while advancing costly clinical programs.
Bioline RX Ltd Sponsored ADR News
BLRX FAQ
What was Bioline RX Ltd Sponsored ADR’s price range in the past 12 months?
Bioline RX Ltd Sponsored ADR lowest stock price was $2.15 and its highest was $7.77 in the past 12 months.
What is Bioline RX Ltd Sponsored ADR’s market cap?
Bioline RX Ltd Sponsored ADR’s market cap is $14.03M.
When is Bioline RX Ltd Sponsored ADR’s upcoming earnings report date?
Bioline RX Ltd Sponsored ADR’s upcoming earnings report date is Aug 13, 2026 which is in 74 days.
How were Bioline RX Ltd Sponsored ADR’s earnings last quarter?
Bioline RX Ltd Sponsored ADR released its earnings results on May 27, 2026. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$1.04 by $1.04.
Is Bioline RX Ltd Sponsored ADR overvalued?
According to Wall Street analysts Bioline RX Ltd Sponsored ADR’s price is currently Undervalued.
Does Bioline RX Ltd Sponsored ADR pay dividends?
Bioline RX Ltd Sponsored ADR does not currently pay dividends.
What is Bioline RX Ltd Sponsored ADR’s EPS estimate?
Bioline RX Ltd Sponsored ADR’s EPS estimate is -0.16.
How many shares outstanding does Bioline RX Ltd Sponsored ADR have?
Bioline RX Ltd Sponsored ADR has 4,368,295 shares outstanding.
What happened to Bioline RX Ltd Sponsored ADR’s price movement after its last earnings report?
Bioline RX Ltd Sponsored ADR reported an EPS of $0 in its last earnings report, beating expectations of -$1.04. Following the earnings report the stock price went up 6.646%.
Which hedge fund is a major shareholder of Bioline RX Ltd Sponsored ADR?
Currently, no hedge funds are holding shares in BLRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bioline RX Ltd Sponsored ADR
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
BLRX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive developments in R&D ventures and strong financial management, offset by minimal revenue growth and reduced operational expenses. The company's strategic focus on innovative treatments and a solid cash position are promising, but current revenue generation and market penetration remain challenges.View all BLRX earnings summariesBLRX Stock 12 Month Forecast
Average Price Target
$12.00
▲(389.80% Upside)
Technical Analysis
Synlogic
―
Moleculin Biotech
―
Citius Pharmaceuticals
―
Chemomab Therapeutics
―
Passage Bio
―
Ownership Overview
―
Insiders
―
Mutual Funds
<0.01% Other Institutional Investors
99.99% Public Companies and
Individual Investors